quali sottogruppi biologici di elezione?
|
|
|
- Gilbert Rodgers
- 8 years ago
- Views:
Transcription
1 Roma, 10 maggio 2013 Meccanismi molecolari di resistenza alle terapie anti-egfr nella neoplasia colorettale metastatica: quali sottogruppi biologici di elezione? Andrea Sartore Bianchi Oncologia Clinica Molecolare Ospedale Niguarda Ca Granda, Milano
2 Different molecular alterations initiate the development of CRC, drive its progression and determine its responsiveness or resistance to antitumor agents Markowitz & Bertagnolli NEJM, 2009
3 Oncogenic activation of PI3K/AKT & RAS/MEK pathways in CRC Fearon ER, Annu. Rev. Pathol. Mech. Dis :
4 There is a clear molecular separation between hypermutated and non-hypermutated CRCs The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252
5 Diversity and frequency of genetic changes leading to deregulation of signalling pathways in CRC The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252
6 The Pandora s jar clinician EREG molecular biologist
7 The Pandora s jar pathologist EREG clinician
8 Established use of biomarkers in 2013 Clinical setting adjuvant first-line liver/lung resection Diagnosis of CRC mcrc MSI KRAS??? Molecular markers advanced chemorefractory disease KRAS* KRAS WT KRAS MT EGFR-targeted therapy layers of molecular selection clinical trials *NRAS, BRAF and PIK3CA (ex20) may further enhance selection for EGFR-targeted therapy
9 Outline 1. Primary resistance to EGFR-targeted therapy in mcrc KRASin CRC: a success of molecular selection for EGFR-targeted monoclonal antibodies Unresolved issues: increased detection sensitivity for KRAS selection; differences among KRAS alleles 2. Other candidate biomarkers of resistance: pros & cons Coexistence of different molecular alterations and multi-determinant analyses 3. Secondary resistance Liquid biopsies to monitor ongoing mutagenesis 4. Implications for the clinical decision making
10 Predictive markers for EGFR-targeted therapeutics in mcrc: a rationale dissection of a molecular pathway for personalized cancer therapy
11
12 Cetuximab Concentration (nm) SW48 DiFi DLD HT-29 SW-480 HCT-116 LoVo SW620 Benvenuti S etal. CancerRes, 2007 % Proliferation (BrdU incorporation)
13 Molecular selection based on KRAS: a successful story 1. It is a relevant molecular alteration in CRC biology 2. Testing provides a digital output (mutated/wt) 3. Reproducible 4. Status in metastatic deposits mirrors primary T 5. High specific negative predictive value: mutated patients display no benefit at all ( 0% RR) 6. Allows huge savings for health care systems
14 What is there beyond KRAS mutations? More on KRAS differences among KRASalleles : G13D mutations versus all others increased detection sensitivity for KRAS selection KRAS amplification What is beyond? solitary KRAS vs multiple signaling path mutations sensitive assessment in a phase III trial The myriad of mechanisms of EGFR resistance Her2 amplification in CRC liquid biopsies to monitor ongoing mutagenesis Integration of molecular knowledge in clinical practice
15 The hypothesis-generating study concerning the role of G13D Percentage alive Any cetuximab therapy No cetuximab therapy* Overall survival p.g13d mutation Other KRAS mutation KRAS wild-type Log-rank p<0.001 Log-rank p=0.49 Log-rank p< Time since randomization Time since randomization Time since randomization or start of cetuximab (mo) or start of cetuximab (mo) or start of cetuximab (mo) *The no cetuximab group for all patients from the pooled data set is the best supportive care group from the C0.17 trial Test for interactionbetween p.g13d mutation vs other KRAS mutationsand overall survival benefit from cetuximab-based treatment (any vs none): P=.003 (HR, 0.30; 95% CI, ) for OS and P=.05(HR, 0.47; 95% CI, ) for PFS. No interaction between p.g13d mutation vs wild-type KRAS status De Roock W et al. JAMA 2010
16 isogenic cell lines In Vitroand In Vivo Effects of p.g13d Mutation on Cetuximab Sensitivity xenografts in immunocompromised mice De Roock W et al. JAMA 2010
17 Treatment Effect on PFS & OS by KRASAllele in Three Phase 3 Studies * * * Positive interaction test Peeters M et al. ESMO 2012
18 Pooled Analysis of Mutant KRAS Alleles Across Panitumumab and Cetuximab Studies * 1 1 * Positive interaction test 1 Tejpar S, et al. J Clin Oncol. 2011; 29:suppl 15; abstract Peeters M et al. ESMO 2012
19 Molecular selection based on KRAS: How deep should we go in testing? ME-PCR Courtesy of Alberto Bardelli
20 The importance of minor clones carrying KRAS mutations on the response to anti-egfr therapy Marchetti A, NEJM 2009; Molinari F et al, CCR 2011
21 Effect of low-frequency KRASmutations on the response to anti-egfr therapy in metastatic colorectal cancer Tougeron D et al., ASCO 212 J Tabernero discussant
22 KRASas the major player of resistance: not only mutations but also (rare) amplifications affects response to anti-egfr therapy Valtorta E, Misale S, Sartore-Bianchi A et al, Int J Cancer 2013
23 EGFR amplification Balanced polisomy Scattered amplification p EGFR CEP7 q Clustered amplification Ch 7
24 EGFR GCN and response to EGFR-targeted moabs Siena S et al. J Natl Cancer Inst, 2009
25 EGFR gene copy number: which cutoff? disomy polisomy 100% disomy 30% polisomy 50% polisomy 60% polisomy response Moroni M, Sartore-Bianchi A, Veronese S & Siena S. Lancet Oncol 2008
26 Standardization of EGFR FISH in colorectal cancer: Results of an international inter-laboratory reproducibility ring study Slide-exchange program to compare EGFR GCN FISH testing results among five pathology reference Centres located in Belgium (University Hospital Gasthuisberg, Leuven), Italy (Ospedale Niguarda Ca Granda, Milano and Istituto Clinico Humanitas, Rozzano), Switzerland (Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno) and United States(University of Colorado School of Medicine, Aurora). Molecular diagnosis of EGFRGCN by FISH varied largely among pathology centres, with fluctuations covering the whole range of proposed cut-offs of predictive usefulness from literature. Definition of a detailed scoring system and implementation of a comprehensive training program for molecular diagnostic laboratories are therefore necessary before including the test into clinical practice Sartore-Bianchi et al. J Clin Pathol, 2011
27 Activation of both PI3K/AKT & RAS/MEK pathways is common in CRC 1 co-activation upon binding to RTK 2 multiple molecular alteration whithin the same tumor Modified from Sarat Chandarlapaty, ASCO 2011
28 Overlapping among molecular alterations in mcrc KRAS xpten 23 In mcrc there is an association between PIK3CA (exon 9) and KRAS mutations (14.7% in KRAS mutants vs 6.8% in KRAS wild types; (p=0.0006) PIK3CA BRAF 3 Sartore-Bianchi et al. PLoS One 2009 De Roock et al. Lancet Oncol2010
29 Effect of multiple molecular alterations within PI3K/AKT & RAS/MEK pathways on response to EGFR-targeted monoclonal antibodies Because of the occurrence of multiple molecular alterationswithin the same tumor, we investigated a cohort of 132 patients treated with EGFR-targeted moabs in the chemorefractory settingby separating patients according to the actual number of molecular abnormalities within the same tumor (i.e. none vs1 vs 2 alterations) among KRAS, BRAF, PIK3CAmutations and loss of PTEN. The probability of response was: 50.0%(22/44) among patients with no alterations, 4.2%(2/47) among patients with 1 alteration and 0%(0/23) for patients with 2 alterations, objective response rate (p< ( quadruple negative ) 1 2+ number of molecular alterations 50% 5% 0% Sartore-Bianchi A et al. PLoS One 2009
30 Study Schema for Pivotal Phase 3 Panitumumab Study (Study ) R A N D O M I Z E Panitumumab 6.0 mg/kg Q2W + BSC Best Supportive Care (BSC) PD PD Follow- up Follow- up 1:1 Primary Endpoint: Progression-free Survival (PFS) PD, progressive disease Peeters et al Clin Cancer Res 2013
31 Evaluated Gene Alterations in the EGFR Signaling Pathway ligand EGFR membrane PI3K/AKT pathways PTEN PIP3 PDK1/2 AKT1/2 PI3K PIP2 P P Grb hsos RAS RAS pathway Signaling RAF MEK1 MEK2 transduction cell survival apoptosis angiogenesis ERK1/2 ß-catenin p53 transcription cell survival proliferation angiogenesis migration Peeters et al Clin Cancer Res 2013
32 Increased PFS Observed in Patients with KRAS Wild-type Tumors Percent Event-free 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Wild-type Median Events / n (%) (weeks) Pmab + BSC 115 / 124 (93) 12.3 BSC Alone 114 / 119 (96) Weeks Hazard Ratio = 0.45 (95% CI: ) 0.59) Stratified Log Rank Test p < Percent Event-free 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Mutant Median Events / n (%) (weeks) Pmab + BSC 76 / 84 (90) 7.4 BSC Alone 95 / 100 (95) Weeks Hazard Ratio = 0.99 (95% CI: ) Quantitative interaction test p < Adapted from Amado et al JCO 4 Peeters et al Clin Cancer Res 2013
33 454 Pyrosequencing Exon Target Linker A Locus-specific sequences DNA barcodes Linker B PCR amplify exons of interest, anneal to beads Emulsion PCR Clonal amplification Deposition of beads onto PTP with 1.6M wells Basepair sequences resolved as flowgrams Technology is commercially available from 454 Life Sciences (Roche)
34 Joint Frequency Distribution of Mutations Across All Gene Pairs Gene - n AKT1 BRAF CTNNB1 EGFR KRAS NRAS PIK3CA PTEN TP53 AKT1 BRAF 1 CTNNB1 EGFR KRAS NRAS 3 PIK3CA PTEN TP tumors had mutations in more than one gene 20 tumors had more than one mutation in a single gene in this analysis Peeters et al Clin Cancer Res 2013
35 WT* KRAS Subset: Response Rate by Central Assessment in the Panitumumab + BSC Arm Genotype BRAF NRAS PIK3CA PTEN n Response Rate (%) WT TP53 Genotype n Response Rate (%) WT MT 9 0 MT WT EGFR WT MT 4 0 MT 0 N/A WT AKT1 WT MT 5 20 MT 1 0 WT Beta- MT 7 14 catenin WT MT 2 50 *WT in codons 12, 13, and 61 Peeters et al Clin Cancer Res 2013
36 WT* KRAS Subset: Relative Risk of Progression or Death of Mutant Genotypes Gene KRAS NRAS BRAF Genotype WT MT KRAS Wild-Type Efficacy Analysis Set PIK3CA PTEN TP53 WT MT WT MT WT MT WT MT WT MT *WT in codons 12, 13, and Favors pmab plus BSC arm No difference in hazard Favors BSC alone arm Peeters et al Clin Cancer Res 2013
37 Mutations in PTEN and/or PI3K do not predict lack of progression on Panitumumab therapy Genotype Hazard Combination Groups N Ratio KRAS WT KRAS, NRAS, BRAF all WT KRAS WT + (PTEN MT or PI3K MT) KRAS WT, PTEN MT, PI3K WT KRAS WT, NRAS WT + (PTEN MT or PI3K MT) KRAS, NRAS, BRAF all WT + (PTEN MT or PI3K MT) Favors Pmab No difference Favors BSC plus BSC arm in hazard alone arm Peeters et al Clin Cancer Res 2013
38 Prognostic Value of the BRAF Mutant Genotype in the KRAS WT* Subset Gene Treatment WT N MT N Hazard Ratio BRAF BSC Pmab + BSC Total Favors MT group No difference in hazard Favors WT group *WT in codons 12, 13, and 61 Peeters et al Clin Cancer Res 2013
39 Other players of primary resistance to EGFR-targeted therapy in mcrc: Her2 Bertotti et al. Cancer Discovery 2011
40 Correlation between HER2 amplification and therapeutic resistance to cetuximab in xenopatients In mcrc patients there is a progressive enrichment of HER2 amplification along with refinement of genetic selection Bertotti et al. Cancer Discovery 2011
41 Effect of anti-egfr and anti-her2 therapies in cetuximab-resistant, HER2-amplified metastatic colorectal cancer xenopatients Bertotti et al. Cancer Discovery 2011
42 HERACLES TRIAL HER2 Amplification for CoLo-rectal Cancer Enhanced Stratification An Open-Label Phase II Study of Lapatinib in Combination With Trastuzumab In Subjects With HER2-amplified Metastatic Colorectal Cancer (mcrc) KRAS Wild Type mcrc oxaliplatin-, irinotecan-, 5-FU, Cmab/Pmab resistant, HER2 amplified Cohort A Cohort B Treatment Cohort A: Lapatinib 1000 mg daily per os + Trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly Cohort B: Pertuzumab 840 mg/kg iv load, followed by 420 mg/kg iv Q3weeks + Trastuzumab 8 mg/kg iv load, followed by 6 mg/kg on day 1 of each subsequent 3 week cycle Statistic Patients in this settings which would respond to a chemotherapy (H0) = 10%; Patients expected to respond to experimental treatment (H1) = 30%; Given α=0.05 and power=0.85, 27 patient (N) are required in each trial cohort (Cohort A 27 + Cohort B 27 = 54 patients overall). Each combination will be considered positive if at least 6 responses/27 patients are observed. Biomarkers Companion Study Cohort A: Patients will be sampled at baseline, every two weeks of each Q3wks cycle (i.e wks 2, wks 4, wks 6, etc), and at disease progression Cohort B: Patients will be sampled at baseline, on Day 1 of each Q3wks cycle, and at disease progression
43 Secondary resistance to targeted therapy in mcrc: an evolving landscape
44 Preclinical models of cetuximab-resistant CRC DiFi Lim1215 Cetuximab-resistantvariants of two colorectal CRC cellular models (DiFiand Lim1215 cells) that are highly sensitive to EGFR inhibition were generated Courtesy of Alberto Bardelli
45 CRC cells become cetuximab-resistant by two distinct mechanisms: 1. KRAS amplification 2. KRAS mutation DiFi DiFi R Lim1215 Lim1215 R Misale et al., Nature 2012
46 Does the DiFi patient exist? PR PR PD PD KRAS amplification in a patient with secondary resistance to panitumumab FISH by Emanuele Valtorta Ospedale Niguarda Ca Granda
47 A platform in place for studying resistance to EGFR-targeted moabs in mcrc at ONCG Start of cmab/pmab (chemorefractory patients) Objective tumor evaluation by RECIST (CT scan, MRI) as per clinical practice Magnetic resonance imaging as early indicator of clinical outcome (experimental) Treatment with anti-egfr moab Patient signs informed consent approved by EC Baseline blood sample for: -ctdna -mirna Analysis on FFPE tissue of: -KRAS/NRAS/BRAF/PIK3CA/PTEN -Her2, KRAS IHC & FISH Blood samples for ctdna and mirna at each time-point associated with response re-evaluation by RECIST (8-12 wks) until PD
48 Mutational status of the KRASgene before and after development of resistance to anti EGFR therapy Patient ID Anti EGFR sensitive tumor KRAS Mutational status (454 a or BEAMing b on tumor) EGFR-targeted monoclonal antibody Anti EGFR resistant tumor KRAS Mutational status (454 a or BEAMing b on tumor) Patient #1 wt pmab + irinotecan wt Patient #2 wt a pmab + irinotecan G13D a Patient #4 wt pmab + irinotecan G13D a Patient #5 wt cmab + irinotecan G13D a Patient #6 wt cmab + FOLFIRI G13D a Patient #7 wt a cmab + irinotecan wt a Patient #8 wt b cmab + irinotecan Q61H b Patient #9 wt b cmab + irinotecan G12D b G13D b Patient #10 wt b pmab wt b Patient #11 wt b pmab wt b KRAS amplified
49
50 Onset of KRASmutations giving rise to resistance is detectable in peripheral blood (liquid biopsies) Patient ID Anti EGFR sensitive KRAS mutational status in plasma Anti EGFR resistant KRAS mutational status in plasma Mutation Percentage Events Mutation Percentage Events Patient #8 wt 0.1% 4/46300 Q61H 1.12% 731/65400 Patient #9 wt 0.03% 0% 3/ /16800 G12D G13D 0.48% 3.3% 89/ /12500 Patient #10 wt 0% 0/85500 wt 0% 0/14200 Misale et al., Nature 2012
51 Patient #8 received a third-line treatment with weekly cetuximab and irinotecan, achieving partial response of liver metastasis maintained for 15 months He was enrolled in our study of secondary resistance to EGFR-targeted therapies and underwent liver biopsy at disease progression August 2009 liver biopsy of the same metastasis that initially responded and then progressed during cetuximab therapy Treatment with anti-egfr moab January 2011
52 Clinical-molecular synopsis RECIST evaluation CEA ctdna (liquid biopsies) Tumor biopsies
53 Montagut et al. Nature Medicine 2012 Bardelli & Janne Nature Medicine 2012
54 Conclusions 1. Molecular selection according to KRASstatus and other downstream effectors (BRAF, PIK3CA) provided a step forward to personalized cancer therapy in mcrc 2. Multiple molecular alterations do occur within the same tumor and multi-determinant evaluation may improve selection 3. Her2is an effector of secondary resistance and a target for therapy 4. We are gaining insights into mechanisms of acquired resistance and KRAS is still a key player (secondary mutations, amplification) 5. Tumor heterogeneity might hamper clinical selection and increased detection sensitivity improve detection of minor clones 6. Liquid biopsies are a tool for monitoring ongoing mutagenesis
55 Integration of new knowledges in clinical practice at Oncologia Niguarda Ca Granda mcrc chemorefractory WT EGFR-targeted therapy KRAS BRAF Her2 EGFR S492R BRAF MGMT met MT regorafenib clinical trials Anti-HER Tx panitumumab LGX818 + MEK162 temozolomide ALK/TRKA/ROS2 unselected NMS anti-alk TAS-102
1. Le mutazioni di KRAS hanno tutte lo stesso significato clinico?
EGFR downstream pathways KRAS domande frequenti ed importanti. Luca Mazzucchelli Istituto cantonale di patologia Locarno )'"* )-# %& # +%,!"# '( "#$ Anti-EGFR monoclonal antibodies (MoAbs) Cetuximab and
Overall survival in metasta0c colorectal cancer and cost of treament
Overall survival in metasta0c colorectal cancer and cost of treament months 20 ~ 24 $ (8 weeks of treatment) 6-8 12-14 BSC 5FU FOLFOX FOLFIRI FOLFOX/ FOLFIRI + cetuximab- bevacizumab Mayo Clinic LV5FU2
Come è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
Colorectal cancer xenopatients: A preclinical platform for precision medicine
Colorectal cancer xenopatients: A preclinical platform for precision medicine Livio Trusolino, MD PhD Laboratory of Molecular Pharmacology IRCC, Institute for Cancer Research and Treatment University of
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
KRAS, NRAS, and BRAF Mutation Analysis in Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: KRAS, NRAS, and BRAF Mutation Analysis in Professional Institutional
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
Metastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months.
TACT-2C Trial A phase II randomized, open-label study evaluating the addiction of trastuzumabto (nabtm)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with
Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
Nuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
Miquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
Seminar N2 Targeted Therapies in Hospital Pharmacy One Problem, Two Views
Dr. Tilman Schöning Heidelberg University Hospital, Germany Seminar N2 Targeted Therapies in Hospital Pharmacy One Problem, Two Views Conflicts of interest Participation in Advisory Boards Amgen GmbH,
!! "# - ' - ) * $ ( ISTITUTO TUMORI MILANO
"!! "# "#'( "# " ) * +, +, - ' - ( STTUTO TUMOR MLANO 1 " "!"# #./01- - -( # * ' ( ' ( ) ' +, #--!. * ) #!"# #!"# STTUTO TUMOR MLANO!"# ' *+*+++,"--!. * ' ( 1 ## ) -!/!00 STTUTO TUMOR MLANO #582#32:5825#24)592
Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy
BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy Soonmyung Paik 1 ; Gyungyub Gong 2 ; Yap Yoon Sim 3 ; Tae- You Kim
Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed
Rilevanza dell innovazione tecnologica per la
Rilevanza dell innovazione tecnologica per la ricerca traslazionale e la terapia in oncologia Ruggero De Maria Dipartimento di Ematologia Oncologia e Medicina Molecolare, Istituto Superiore di Sanità Translational
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
Personalized Predictive Medicine and Genomic Clinical Trials
Personalized Predictive Medicine and Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov brb.nci.nih.gov Powerpoint presentations
Corporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
New Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
WHITE PAPER SEPT 2015
WHITE PAPER SEPT 2015 LIQUID BIOPSY FOR THE DETECTION AND MONITORING OF CANCER: ANALYSIS OF 96 HOTSPOT MUTATIONS VIA PLASMA DERIVED CIRCULATING TUMOR DNA PATHWAY GENOMICS CANCER AND SOMATIC MUTATIONS The
Trials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
Analysis of KRAS/NRAS and BRAF mutations in FIRE-3
Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles
Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles FOM Lille 2013 1 Her2 breast cancer expression = Poor
Genomic Clinical Trials: NCI Initiatives
Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
How can we generate economic value from personalized medicine and big data analysis?
Estonian Health Innovation Forum 2015 Focus on Personalised Medicine How can we generate economic value from personalized medicine and big data analysis? Jonathan Knowles October 26, 2015 Tallinn, Viru
Molecular markers and clinical trial design parallels between oncology and rare diseases?
Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe
Clinical development of AZD9291 in non-small cell lung cancer
Clinical development of AZD9291 in non-small cell lung cancer Rachael Lawrance (AstraZeneca) PSI One Day Meeting: The Innovative, Challenging and Diversified World of Respiratory Disease 13 Nov 2015 Overview
Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Update on neoadjuvant treatment of breast cancer
Update on neoadjuvant treatment of breast cancer «IS PATHOLOGIC COMPLETE RESPONSE STILL A GOOD SURROGATE OF SURVIVAL?» Complete histological response varies according to tumoral type pcr (%) 40 35 30 25
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes
Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
Cáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta
Cáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Advanced NSCLC: chemotherapy has reached a therapeutic
Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku
11 th International Congress on Targeted Anticancer Therapies Paris March 4-6, 2013 Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku Investigational Cancer Therapeutics (Phase
ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology
ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:
New Approval Mechanism for Breast Cancer using pathologic Complete Response
New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine
Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
El papel de la anatomía patológica en oncología: presente y futuro. The role of pathological anatomy in oncology: present and future
El papel de la anatomía patológica en oncología: presente y futuro The role of pathological anatomy in oncology: present and future Federico Rojo Fundación Jiménez Díaz, Madrid All patients with same diagnosis:
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
The EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry
The American Journal of Surgery (2013) 205, 608-612 North Pacific Surgical Association Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer
PI3K signaling pathway a new target for breast cancer treatment
PI3K signaling pathway a new target for breast cancer treatment Introduction At the 37 th annual San Antonio Breast Cancer Symposium, SABCS, a number of interesting research trends, novelties as well as
PATHOLOGY. HercepTestTM. Product Information
PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying
HER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
Targeted Therapy in an Era of Genomic Medicine. George W. Sledge MD Stanford University
Targeted Therapy in an Era of Genomic Medicine George W. Sledge MD Stanford University Why Do Women Die of Breast Cancer? Bad biology Avoidable deaths Important subsets of breast cancers defined by molecular
Management of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
Foundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Nuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012
Nuovi Scenari in Oncologia G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012 WHAT is cancer? «Cancer is a genetic disease of the somatic cell» [B. Vogelstein] Ten years ago Now [Cell.
Metastatic Triple Negative Breast Cancer: Ongoing Trials. Joan Albanell Hospital del Mar, Barcelona
Metastatic Triple Negative Breast Cancer: Ongoing Trials Joan Albanell Hospital del Mar, Barcelona Metastatic Triple Negative Breast Cancer Spectrum Targeting Growth Factor Receptors Targeting Signaling
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder
Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder Professor Claus Lindbjerg Andersen Department of Molecular Medicine (MOMA) Aarhus University hospital Outline The central
ESMO 2014 Summary Breast Cancer
ESMO 2014 Summary Breast Cancer 1 7. 1 0. 2 0 1 4 A N NA D U R I G OVA M E D I C A L O N CO LO GY U N I V E R S I T Y H O S P I TA L S O F G E N E VA Outline 1. Early Breast Cancer Her2+ Neoadjuvant: Lapatax
Primary Care Management of Colorectal Cancer
Primary Care Management of Colorectal Cancer Dr. Dan Renouf, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Primary Care Management of Colorectal Cancer Survivors Daniel
What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents
Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents J. Jack Lee, Ph.D. Department of Biostatistics 3 Primary Goals for Clinical Trials Test safety and
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
Moving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 9/1/2011 Most Recent Review Date (Revised): 1/27/2015 Effective Date: 11/2/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
FARMACI PERSONALIZZATI PER
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI
Gebruik van predictieve markers voor targeted therapy in de algemene praktijk
Gebruik van predictieve markers voor targeted therapy in de algemene praktijk Gerrit A. Meijer, MD, PhD Professor of Pathology Chair of the Department of Pathology VU Universtiy Medical Center Amsterdam
Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
Anticorpi monoclonali nel trattamento del carcinoma colorettale IL TRATTAMENTO DI PRIMA LINEA NELLA MALATTIA AVANZATA
Anticorpi monoclonali nel trattamento del carcinoma colorettale IL TRATTAMENTO DI PRIMA LINEA NELLA MALATTIA AVANZATA New Drugs in CRC Irinotecan Oxaliplatin Oral Fluoropyrimidines (CAP-UFT) Bevacizumab
BRAF Testing in Advanced Colorectal Cancer: Is It Ready for Prime Time?
BRAF Testing in Advanced Colorectal Cancer: Is It Ready for Prime Time? Brooke Phillips, MD, Matthew Kalady, MD, and Richard Kim, MD Dr. Phillips is a fellow in the Department of Oncology at the Taussig
Mechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
Resminostat In Advanced Hepatocellular Carcinoma (HCC): Overall Survival Subgroup Analysis Of Prognostic Factors In The SHELTER Trial
Resminostat in HCC Resminostat In Advanced Hepatocellular Carcinoma (HCC): Overall Survival Subgroup Analysis Of Prognostic Factors In The SHELTER Trial Michael Bitzer, Tom M. Ganten, Henning Wege, Edoardo
Inflammatory Breast Cancer: A Unique Pathologic Entity?
Inflammatory Breast Cancer: A Unique Pathologic Entity? Sandra M. Swain, M.D. Director, Washington Cancer Institute Washington Hospital Center Washington DC Outline Overview Therapy High dose chemotherapy
Guideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
Innovation: Present Meets Future
Innovation: Present Meets Future SOCIAL INNOVATION Leading Innovation in the Cooperative Group Setting Craig Nichols, M.D. BEST OF SWOG Barlogie-Salmon Myeloma Committee Robert Z. Orlowski, M.D., Ph.D.
10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
Pulmonary and Critical Care Regional Symposium April 25, 2015
Pulmonary and Critical Care Regional Symposium April 25, 2015 2015: Molecular Medicine, Resistance Mutations and Immunotherapy. Keeping Up With The Latest in NSCLC Barbara J. Gitlitz MD Associate Professor
Molecular Diagnosis of Gastrointestinal Tumors
Molecular Diagnosis of Gastrointestinal Tumors Zoltan Szentirmay National Institute of Oncology Center of Surgical and Molecular Tumor Pathology EEA and Norwegian Financial Mechanisms in Hungary, Development
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
Integration of Molecular Biomarkers into Clinical Development
WHITE PAPER Integration of Molecular Biomarkers into Clinical Development Eric Groves, MD, PhD, Executive Global Strategic Drug Development Director, Quintiles; Jason Hill, PhD, Associate Director, External
MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.